Efficacy and safety of Thai herbs, Benchalokawichian and Junleela, for COVID-19 patients

Phase 3

Completed

• Conditions: COVID-19 infection; SAR-CoV-2 viral load; Emerging Disease; Molnupiravir; Infectious Disease

• Registration Number: TCTR20240323007
• Lead Sponsor: Srinakharinwirot University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-12-31
• Study Start: 2024-03-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 79

Inclusion Criteria

age 20-60 years old, with a positive result for COVID-19 through an Antigen Test Kit (ATK) and experiencing at least one symptom of upper respiratory tract infection(URI) not exceeding 5 days.

Exclusion Criteria

critical conditions requiring hospitalization, abnormal findings in chest X-rays, uncontrolled chronic diseases, severe allergies to herbal medicines, pregnant or lactating women, immunocompromised host, stage 3 or higher chronic kidney disease (CKD), cerebrovascular diseases, obesity, liver diseases, and a lymphocyte count of less than 1,000 cells/microliter.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Viral quantity at 0, 6 days after the intervention viral PCR,Interleukin-6 at 0, 6 days after the intervention the laboratory method by which Interleukin-6 is measured

Secondary Outcome Measures

Name	Time	Method
safety at 0, 6 days after the intervention CBC, creatinine, AST, ALT,COVID-19 signs and symptoms at 0, 6 days after the intervention subjective data